CTT Pharmaceutical (CTTH) CEO adds 7,700 shares in open market purchase

Rhea-AI Filing Summary

CTT Pharmaceutical Holdings, Inc. reported that its CEO purchased 7,700 CTTH shares on August 7, 2026 in a non-derivative open market or private transaction at $0.065 per share. Following this purchase, the CEO directly owns 9,353,656 shares of CTTH. The transaction was not marked as pursuant to a Rule 10b5-1 trading plan.

Insider Trade Summary

Net Buyer: 7,700 shares

Net Buy 1 txn

Insider CTT PHARMACEUTICAL HOLDINGS, INC.

Role CEO

Bought 7,700 shs ($500.50)

Type	Security	Shares	Price	Value
Purchase	CTTH	7,700	$0.065	$500.50

Holdings After Transaction: CTTH — 9,353,656 shares (Direct)

Key Figures

Shares purchased: 7,700 shares Purchase price: $0.065 per share Shares owned after transaction: 9,353,656 shares +1 more

4 metrics

Shares purchased 7,700 shares Non-derivative open market or private purchase on August 7, 2026

Purchase price $0.065 per share Price paid for CTTH shares in the August 7, 2026 transaction

Shares owned after transaction 9,353,656 shares Direct CTTH holdings after the reported purchase

Net buy shares 7,700 shares Net share change across all reported transactions in this filing

Key Terms

open market or private transaction, non-derivative, Rule 10b5-1 trading plan

3 terms

open market or private transaction financial

"Transaction code description: Purchase in open market or private transaction"

non-derivative financial

"Transaction type is classified as non-derivative for the CTTH shares"

Rule 10b5-1 trading plan financial

"The Rule 10b5-1 checkbox (aff_10b5_one) is reported as false for this filing"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 08/10/2026 - 09:48 AM Accepted by SEC EDGAR 08/10/2026 - 09:47 AM Learn about SEC filing dates

FAQ

What insider transaction did CTTH report in this Form 4?

CTT Pharmaceutical Holdings, Inc. reported that its CEO purchased 7,700 CTTH shares on August 7, 2026 in a non-derivative open market or private transaction at $0.065 per share.

How many CTTH shares does the insider own after this transaction?

After the August 7, 2026 purchase, the CEO of CTT Pharmaceutical Holdings, Inc. directly owns 9,353,656 CTTH shares, as reported in the Form 4 filing for this non-derivative transaction.

Was the recent CTTH insider share purchase under a Rule 10b5-1 plan?

No. The Form 4 for CTT Pharmaceutical Holdings, Inc. shows the Rule 10b5-1 checkbox as not affirmed, indicating the 7,700-share purchase was not reported as made under a Rule 10b5-1 trading plan.

What price did the CTTH insider pay for the purchased shares?

The CEO of CTT Pharmaceutical Holdings, Inc. purchased 7,700 CTTH shares at $0.065 per share on August 7, 2026, in a non-derivative open market or private transaction, according to the Form 4 data.

Was the CTTH insider transaction a buy or a sell?

The reported insider activity for CTT Pharmaceutical Holdings, Inc. on August 7, 2026 was a purchase of 7,700 CTTH shares. The Form 4 classifies it as a non-derivative buy transaction, with no corresponding sales reported.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

CTT PHARMACEUTICAL HOLDINGS, INC.

(Last) (First) (Middle)

3853 NORTHDALE BLVD #268

(Street)

TAMPA FLORIDA 33624

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
CTT PHARMACEUTICAL HOLDINGS, INC. [ CTTH ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CEO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/07/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
CTTH	08/07/2026		P		7,700	A	$0.065	9,353,656	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	Ryan Khouri	08/10/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)